

Michael P Findlay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3978617/publications.pdf>

Version: 2024-02-01

16
papers

663
citations

1307594

7
h-index

1058476

14
g-index

16
all docs

16
docs citations

16
times ranked

1307
citing authors

#	ARTICLE	IF	CITATIONS
1	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	10.7	293
2	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. <i>Annals of Surgical Oncology</i> , 2017, 24, 2252-2258.	1.5	186
3	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	2.3	54
4	Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. <i>Npj Genomic Medicine</i> , 2018, 3, 18.	3.8	37
5	Platinum-specific detection and quantification of oxaliplatin and Pt(R,R-diaminocyclohexane)Cl ₂ in the blood plasma of colorectal cancer patients. <i>Journal of Analytical Atomic Spectrometry</i> , 2008, 23, 881.	3.0	22
6	Summary scores captured changes in subjects' QoL as measured by the multiple scales of the EORTC QLQ-C30. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 895-902.	5.0	22
7	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
8	Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 533-542.	2.3	10
9	A caseâ€“control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidineâ€“induced gastrointestinal toxicity. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 155-164.	2.4	4
10	Gene expression profiling of breast tumours from New Zealand patients. <i>New Zealand Medical Journal</i> , 2017, 130, 40-56.	0.5	4
11	Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors. <i>Clinical Breast Cancer</i> , 2017, 17, 139-153.	2.4	3
12	Comparison of a thymine challenge test and endogenous uracilâ€“dihydrouracil levels for assessment of fluoropyrimidine toxicity risk. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 711-716.	2.3	3
13	A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 739-748.	2.3	2
14	Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 817-820.	1.6	1
15	Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. <i>New Zealand Medical Journal</i> , 2021, 134, 120-128.	0.5	1
16	Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma. <i>American Journal of Cancer</i> , 2005, 4, 159-168.	0.4	0